

Immunoproteomic analysis of lymphocyte secretion fluid in patients with acute phase typhoid fever in Bangladesh

Richelle C. Charles^{1,2†}, Li Liang^{3†}, Farhana Khanam⁴, Daniel T. Leung^{1,2},
Jeremy Farrar⁵, Stephen Baker⁵, Albrecht Ludwig⁶, Stephen B.
Calderwood^{1,2,7}, Firdausi Qadri^{4‡}, Phil Felgner^{3‡}, Edward T. Ryan^{1,2,8‡}

¹Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; ²Department of Medicine, Harvard Medical School, Boston, MA, USA; ³Department of Medicine, University of California, Irvine, Irvine, California; ⁴International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh; ⁵Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; ⁶Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany; ⁷Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA, USA; ⁸Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA († co-first, ‡co-senior)

Lymphocyte secretion assay: TPTTest

ALS: *antibody in lymphocyte supernatant*

- 1 cc blood
- Buffy coat or PBMCs.
- Culture 37C 18-48 hours in media, unstimulated
- Recover supernatant
- Can use in ELISA or dot blot assays
- These cells reflect “in vivo” stimulated cells
- They are acute phase
- Could consider this analysis an “antibody amplification assay”

Antigen-Specific Immunoglobulin A Antibodies Secreted from Circulating B Cells Are an Effective Marker for Recent Local Immune Responses in Patients with Cholera: Comparison to Antibody-Secreting Cell Responses and Other Immunological Markers

Firdausi Qadri,^{1*} Edward T. Ryan,^{2,3,4} A. S. G. Faruque,¹ Firoz Ahmed,¹ Ashraful Islam Khan,¹ M. Monirul Islam,¹ Syed M. Akramuzzaman,¹ David. A. Sack,¹ and Stephen B. Calderwood^{3,5}

International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Mohakhali, Dhaka 1212, Bangladesh¹; Tropical & Geographic Medicine Center,² Division of Infectious Diseases,³ Massachusetts General Hospital, Boston, Massachusetts 02114; and Department of Immunology and Infectious Diseases, Harvard School of Public Health,⁴ and Department of Microbiology and Molecular Genetics, Harvard Medical School,⁵ Boston, Massachusetts 02115

Received 5 February 2003/Returned for modification 21 April 2003/Accepted 24 May 2003

Gut-derived lymphocytes transiently migrate through the peripheral circulation before homing back to mucosal sites and can be detected using an ELISPOT-based antibody secreting cell (ASC) assay. Alternatively, transiently circulating lymphocytes may be cultured in vitro

CLINICAL AND VACCINE IMMUNOLOGY, NOV. 2009, p. 1587–1594
1556-6811/09/\$12.00 doi:10.1128/CVI.00311-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Vol. 16, No. 11

Salmonella enterica Serovar Typhi-Specific Immunoglobulin A Antibody Responses in Plasma and Antibody in Lymphocyte Supernatant Specimens in Bangladeshi Patients with Suspected Typhoid Fever^V

Alaullah Sheikh,^{1†} M. Saruar Bhuiyan,^{1†} Farhana Khanam,¹ Fahima Chowdhury,² Amit Saha,¹ Dilruba Ahmed,¹ K. M. A. Jamil,¹ Regina C. LaRocque,² Jason B. Harris,² Mian Mashhud Ahmad,³ Richelle Charles,² W. Abdullah Brooks,¹ Stephen B. Calderwood,^{2,4,5} Alejandro Cravioto,¹ Edward T. Ryan,^{2,4,6} and Firdausi Qadri^{1*}

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh¹; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts²; Dhaka Medical College Hospital, Dhaka, Bangladesh³; Department of Medicine, Harvard Medical School, Boston, Massachusetts⁴; Department of Microbiology and Molecular Center, Harvard Medical School, Boston, Massachusetts⁵; and Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts⁶

Received 29 July 2009/Returned for modification 28 August 2009/Accepted 31 August 2009

Many currently available diagnostic tests for typhoid fever lack sensitivity and/or specificity, especially in areas of the world where the disease is endemic. In order to identify a diagnostic test that better correlates with typhoid fever, we evaluated immune responses to *Salmonella enterica* serovar Typhi (serovar Typhi) in individuals with suspected typhoid fever in Dhaka, Bangladesh. We enrolled 112 individuals with suspected typhoid fever, cultured day 0 blood for serovar Typhi organisms, and performed Widal assays on days 0, 5, and 20. We




FIG. 5. MP- and WC-specific IgA responses in ALS specimens of different study groups on different days. Geometric means with the SEM are shown for day 0 (D0), day 5 (D5), and day 20 (D20). Statistical significance: * $P < 0.0001$; ** $P < 0.005$; * $P < 0.05$. Statistical difference compared to GrV: φ, $P < 0.05$.

ALS responses to MP
(membrane preparation)
fall by day 20

TABLE 2. MP specific IgA responses in plasma and ALS specimens at the acute stage of disease*

Group	Characteristics	Sample size	IgA response (%)	
			Plasma	ALS
I	Blood culture positive	26	21 (81)	26 (100)
II	Fourfold Widal titer change	13	8 (58)	13 (100)
III	≥320 Widal titer	41	18 (43)	29 (70)
IV	Culture negative, Widal negative but a >10 ELISA unit ALS response	14	4 (29)	14 (100)
V	Culture negative, Widal negative and a ≤10 ELISA unit ALS response	18	5 (28)	0 (0)

* Analyses of specimens on study day 1 from patients subgrouped according to different clinical and immunological characteristics. Positive responses were calculated as >GM plus two standard deviations of healthy control results; plasma MP-IgA response cutoff, ≥61 ELISA units; ALS MP-IgA response cutoff, >10 ELISA units.

Protein Microarray

- Collaborators: Li Liang and Phil Felgner; UC Irvine
- *Salmonella* arrays contain ~ 2000 proteins including membrane proteins and others predicted by software to potentially be immunogenic
- Proteins are expressed in 96 well plates using *E coli* in vitro transcription and translation kits before being spotted on to a nitrocellulose-coated glass slides.

Samples


- 1) Typhoid Positive samples, n=10
- 2) Healthy controls, n=5
- 3) Other febrile illness, n=5

Each sample was probed with the following secondary Antibodies


- 1) Biotin-conjugated α -Human IgA
- 2) Biotin-conjugated α -Human IgG

Typhi Patient (STFL-176)

Biotin- IgG




Biotin- IgA




Biotin-IgA


Typhi patient




Healthy control




TB




ALS - IgA




ALS - IgG



Seroreactive Antigens - IgA




Seroreactive Antigen




Locus	Gene	Function
t1477	hlyE	haemolysin HlyE
t2315	fimF	fimbria-like protein FimF precursor
t2394		conserved hypothetical lipoprotein
t0500	dedD	DedD protein
		periplasmic dipeptide transport protein
t3885	dppA	precursor
t2294		hypothetical protein
t1649	tonB	TonB protein
t1128		putative heat shock protein
t0022	bcfA	fimbrial subunit
t2561	safA	probable lipoprotein
t4447	ytfB	conserved hypothetical protein
t2220	rlpB	rare lipoprotein B precursor
		thiol:disulfide interchange protein DsbG
t2261	dsbG	precursor
t3116		conserved hypothetical protein
t4631	sthD	putative fimbrial subunit
t2229	rlpA	rare lipoprotein A
t3414		hypothetical protein


Seroreactive Antigens - IgG




Seroreactive Antigens




IgG



Seroreactive antigens alignment between IgG & IgA




Seroreactive antigens Common to both IgG & IgA



Ty2	CT18	LT2	Gene Name	Function
t1477	STY1498		hlyE	haemolysin HlyE
t2561	STY0332		safA	probable lipoprotein
t1128	STY1871	STM1251		putative heat shock protein conserved hypothetical protein
t4447	STY4752	STM4396	ytfB	hypothetical protein
t0022	STY0024	STM0021	bcfA	fimbrial subunit
t4631	STY4940	STM4592	sthD	putative fimbrial subunit
t1341	STY1649	STM1473		outer membrane protein
t0190	STY0207		staA	putative fimbrial protein


Seroreactive antigens specific to IgA

Ty2	CT18	LT2	Gene Name	Function
T2315	STY0595	STM0548	fimF	fimbria-like protein FimF precursor
T2394	STY0509	STM0465		conserved hypothetical lipoprotein
T0500	STY2595	STM2364	dedD	DedD protein
T3885	STY4168	STM3630	dppA	periplasmic dipeptide transport protein precursor
T2294	STY0616	STM0567		hypothetical protein
T3414	STY3672			hypothetical protein
T3759	STY4029	STM3758	fidL	putative exported protein
T0955	STY2131	STM1922	motB	motility protein B
T2274	STY0638	STM0594	fepB	ferrienterobactin-binding periplasmic protein precursor
T1992	STY0937	STM0941	ybjY	putative exported protein
T1116	STY1880a	STM1244	pagD	putative outer membrane virulence protein
T2575	STY0314			probable secreted protein
T2319	STY0590	STM0544	fimI	Putative fimbrial-like protein fimI
T0394	STY2701	STM2465	eutN	Putative ethanolamine utilization protein EutN
T2126	STY0796	STM0750	ybgF	putative exported protein



IgA specific
(n=25)

Seroreactive antigens specific to IgG



Ty2	CT18	LT2	Gene Name	Function
t4225	STY4519	STM4319	phoN	nonspecific acid phosphatase precursor
t1111	STY1886		cdtB	putative toxin-like protein
t0623	STY2467	STM1051	sspH2	secreted effector protein
t1713	STY1247	STM1207		putative lipoprotein
t1476	STY1499			hypothetical protein
t1781	STY1176	STM1139	csgG	assembly/transport component in curli production
t2457	STY0444	STM0406	yajC	putative membrane protein
t2787	STY3008	STM2885	sipB	pathogenicity island 1 effector protein
t2558	STY0336	STM0301	safC	outer-membrane fimbrial usher protein
t3352	STY3614	STM3945		possible exported protein
t1870	STY1070			putative bacteriophage protein

Characterization of Anti-*Salmonella enterica* Serotype Typhi Antibody Responses in Bacteremic Bangladeshi Patients by an Immunoaffinity Proteomics-Based Technology^{V‡}

Richelle C. Charles,^{1,2}§* Alaullah Sheikh,³§ Bryan Krastins,⁴ Jason B. Harris,^{1,2} M. Saruar Bhuiyan,³ Regina C. LaRocque,^{1,2} Tanya Logvinenko,⁵ David A. Sarracino,⁴ Indira T. Kudva,⁶ Jana Eisenstein,¹ Michael J. Podolsky,¹ Anuj Kalsy,¹ W. Abdullah Brooks,³ Albrecht Ludwig,⁷ Manohar John,⁸ Stephen B. Calderwood,^{1,2,9} Firdausi Qadri,^{7,†} and Edward T. Ryan^{1,2,10}†

Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts¹; Department of Medicine, Harvard Medical School, Boston, Massachusetts²; International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh³; Thermo Fisher Scientific, Cambridge, Massachusetts⁴; Biostatistics Research Center, ICDDR,B⁵; Tufts University Medical Center, Boston, Massachusetts⁶; Food Safety

National Centers for Animal Health, USDA-ARS, Ames, Iowa⁷; Institut für Krankenhaushygiene, Klinikum der Johann Wolfgang Goethe-University, Frankfurt am Main, Germany⁸; Pathovacs Incorporated, Ames, Iowa⁹; Department of Molecular Genetics, Harvard Medical School, Boston, Massachusetts¹⁰

Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, Massachusetts¹¹

Received 9 March 2010/Returned for modification 19 May

Salmonella enterica serotype Typhi is the cause of typhoid fever and available typhoid vaccines provide 50 to 90% protection for 2 to 5 years. Current assays to identify individuals with typhoid fever lack sensitivity and/or

IPT TO CHARACTERIZE *S. TYPHI* IMMUNOPROTEOME 1193




FIG. 1. Characterization of anti-HlyE immune responses. Anti-HlyE IgG (A) and IgA (B) responses in the plasma of North American volunteers (NA) and acute-phase (day 0) and convalescent-phase (day 20) plasma of patients infected with *S. Typhi* or *V. cholerae* (control). (C) Anti-HlyE IgA ALS responses in day 0, day 6, and day 20 samples of patients infected with *S. Typhi* and in day 2 and day 7 samples of patients infected with *V. cholerae* (control).

Summary

- We have identified a sub-set of proteins in MP, that can be advanced for next generation TPTTest based detection systems.
- We have found that TPTTest fluid is both sensitive and specific for detecting acute stage infection, even in edemic zones.
- These findings probably also applicable to other infections.

- **Acknowledgements:** This work was supported by the icddr,b and grants from the National Institutes of Health, including the National Institute of Allergy and Infectious Diseases (AI100023 and AI077883 [E.T.R., F.Q.], AI058935 (S.B.C, E.T.R and F.Q.), AI073672 (L.L., P.F.), AI078213 (L.L., P.F.), Training Grant in Vaccine Development and Public Health (D43 TW005572 [F.K., E.T.R, F.Q.]), Career Development Awards (K08 AI089721 [R.C.C.], K08 AI100923 [D.T.L.]), an American Recovery and Reinvestment Act (ARRA) Post-doctoral Fellowship in Global Infectious Diseases (TW005572 [D.T.L., R.C.C]), a Clinical Research Scholars Award (R24 TW007988 [S.B.C]) from the Fogarty International Center, a Massachusetts General Hospital Physician Scientist Development Award from Massachusetts General Hospital (R.C.C), a Burroughs Welcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases (D.T.L.), and grants from the Deutsche Forschungsgemeinschaft (LU 842/1-1).